Active Components of Chinese Medicine Against Liver Fibrosis Based on PI3K/Akt Signaling Pathway： A Review
10.13422/j.cnki.syfjx.20230202
- VernacularTitle:基于PI3K/Akt信号通路探讨中药活性成分抗肝纤维化的研究现状
- Author:
Xing YANG
1
;
Zhen WANG
2
;
Shudi LI
1
;
Jiangkai LIU
2
;
Suling LI
2
Author Information
1. Henan University of Chinese Medicine，Zhengzhou 450046，China
2. The First Affiliated Hospital of Henan University of Chinese Medicine，Zhengzhou 450000，China
- Publication Type:Journal Article
- Keywords:
Chinese medicinal monomer;
phosphatidylinositol 3-kinase （PI3K）/protein kinase B （Akt）;
signaling pathway;
liver fibrosis;
hepatic stellate cells
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2023;29(13):230-240
- CountryChina
- Language:Chinese
-
Abstract:
Hepatic fibrosis is a pathological reparative response of the liver to chronic injury and a crucial step in the progression of chronic liver disease， characterized mainly by the activation of hepatic stellate cells and diffuse deposition of extracellular matrix. Currently， there is no ideal specific drug for the treatment of liver fibrosis in clinical practice. In recent years， with the development and progress of traditional Chinese medicine （TCM） in the treatment of liver fibrosis， TCM has been widely recognized for its significant therapeutic effect and fewer adverse reactions. The phosphatidylinositol 3-kinase （PI3K）/protein kinase B （Akt） signaling pathway is an important pathway that affects the formation and development of liver fibrosis. It mainly plays a role in liver fibrosis by inhibiting the activation and proliferation of hepatic stellate cells， promoting their apoptosis， reducing oxidative stress in liver cells， decreasing the deposition of extracellular matrix， and enhancing liver cell autophagy. This article summarized the mechanisms by which Chinese medicinal monomers regulated the PI3K/Akt pathway to exert their effects on liver fibrosis and their synergistic effects with other signaling pathways， providing a theoretical basis and references for the development of new drugs for the treatment of liver fibrosis with TCM.
